Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. FIRST AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENTConfidential Treatment • March 2nd, 2011 • Dyax Corp • Services-commercial physical & biological research
This FIRST AMENDMENT (the “First Amendment”), dated as of December 21, 2010 (the “Amendment Date”), is entered into by and between Dyax Corp., with principal offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. (“Dyax”), and Defiante Farmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal (“Defiante”). This First Amendment amends that certain Joint Development and License Agreement (the “Original Agreement”), dated effective as of June 18, 2010 (the “Effective Date”) by and between Dyax and Defiante. All capitalized terms not otherwise defined in this First Amendment shall be as defined in the Original Agreement.
